再灌注性心律失常的临床特点与治疗

目的：探讨尿激酶静脉溶栓治疗急性心肌梗死（AMI）再通后发生再灌注性心律失常（RA）的特点。评价镁剂对RA的治疗。方法：将107例AMI住院患者全部地扩酶静脉溶栓治疗，然后将其分成A组（50例）和B组（57例）；B组在溶栓治疗前20分钟静脉注入镁剂。结果：两组溶栓患者根据临床判定标准判定再通69例，再通率为64．49％。溶栓前发生心律失常36例。A组31例再通患者中25例发生RA，B组38例再通患者中13例发生RA（P＜0．01）。结论：RA是AMI溶栓治疗成功后的重要并发症，表现为各种类型，尤以室性RA为主。镁剂对治疗RA有重要作用。

Clinical features and treatment for reperfusion arrhythmia

Objective To investigate clinical features of reperfusion arrhythmia (RA) following venous thrombolytic therapy by use of Urokinase (UK) for treating acute myocardial infarction (AMI),and to evaluate the effect of magnesium agent in treating RA.Methods 107 AMI cases admitted to our hospital were treated with UK who were divided into A (n=50) and B (n=57) groups.In B magnesium agent was injected into vein 20 minutes before thrombolytic therapy.Results According to clinical criteria,69 cases were recanalyzed with a recanalyzed rate of 64.49%.Before thrombolytic therapy,arrhythmia occurred in 36 cases.Of 31 recanalyzed cases in A group,25 cases presented with RA,whereas,of 38 recanalyzed cases in B group,13 cases presented with RA (P<0.01).Conclusion RA is the major complication of AMI following successful thrombolytic therapy characterized by ventricular RA.Magnesium agent plays an important role in treating RA.